Antibiotic prescribing practices during the COVID-19 pandemic: A post-hoc analysis of the Adaptive COVID-19 Treatment Trial

Clicks: 3
ID: 324944
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #92 of 208 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Background The COVID-19 pandemic exacerbated antibiotic overuse; however, gaps remain regarding the timing of administration and whether prescribing is supported by evidence of bacterial infection. Methods Antibiotic use was described within the Adaptive COVID-19 Treatment Trial (ACTT), a series of randomized controlled therapeutics trials in adults hospitalized with COVID-19 from Feb 2020-May 2021. Proportions of participants receiving antibiotics by trial stage were described (overall, pre-randomization, post-randomization). Analyses were repeated for CDC’s National Healthcare Safety Network (NHSN) categories and for antibiotics used for community-acquired pneumonia (CAP) according to IDSA guidelines. In ACTT-2 and ACTT-4, lab culture results were documented for Grade 3 or greater infection adverse events; proportions of antibiotic recipients with a positive culture were compared between trials. Results Most (62%) of the 4,074 participants received at least one antibiotic. Pre-randomization antibiotic use declined across ACTT stages, from 72% in ACTT-1 to 32% in ACTT-4. The largest decrease noted is within the NHSN category for community-acquired infection (decreasing significantly from 49% in ACTT-1 to 24% in ACTT-4). Post-randomization use was lower and declined modestly, from 28% to 18%. The percentage of post-randomization antibiotic recipients with a positive bacterial culture was 18% in ACTT-2 and 18% in ACTT-4. Conclusions Antibiotic use decreased substantially over the first pandemic year, however in-hospital prescribing remained common despite limited microbiologic confirmation of infection. Stewardship efforts during future respiratory viral pandemics should focus on reducing empiric antibiotic use for CAP-like illness at presentation and on strengthening reassessment, diagnostic stewardship, and de-escalation of later in-hospital antibiotic therapy.
Reference Key
openalex_W7202357585 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Catharine I. Paules, Kevin Rubenstein, Kay M. Tomashek, Tyler Bonnett, Nadine Rouphael, Zanthia Wiley, Varduhi Ghazaryan, Rekha R. Rapaka, Gail E. Potter
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag503
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.